GREENBROOK ANNOUNCES SETTLEMENT OF LAWSUIT WITH BENJAMIN KLEIN
Greenbrook TMS Inc. (OTC: GBNHF) has reached a settlement agreement with Benjamin Klein and other plaintiffs to resolve a lawsuit filed in Delaware. The settlement includes a cash payment of US$800,000, the transfer of 12 Treatment Center locations in New Jersey to Klein, and payment of approximately US$110,000 in payroll taxes. In return, Klein will relinquish 11,634,660 common shares of Greenbrook, which will be cancelled. This reduces the total outstanding shares to 33,967,600. The settlement is expected to close around August 15, 2024. Greenbrook's CEO, Bill Leonard, expressed satisfaction in resolving the dispute, allowing the company to focus on its core business operations and growth.
Greenbrook TMS Inc. (OTC: GBNHF) ha raggiunto un accordo di transazione con Benjamin Klein e altri querelanti per risolvere una causa intentata in Delaware. L'accordo prevede un pagamento in contante di 800.000 dollari USA, il trasferimento di 12 sedi di centri di trattamento nel New Jersey a Klein, e il pagamento di circa 110.000 dollari USA in tasse su salari. In cambio, Klein dovrà rinunciare a 11.634.660 azioni ordinarie di Greenbrook, che saranno annullate. Questo riduce il totale delle azioni in circolazione a 33.967.600. Si prevede che l'accordo venga concluso intorno al 15 agosto 2024. Il CEO di Greenbrook, Bill Leonard, ha espresso soddisfazione per la risoluzione della disputa, consentendo all'azienda di concentrare le sue operazioni commerciali e la crescita.
Greenbrook TMS Inc. (OTC: GBNHF) ha llegado a un acuerdo de conciliación con Benjamin Klein y otros demandantes para resolver una demanda presentada en Delaware. El acuerdo incluye un pago en efectivo de 800,000 dólares estadounidenses, la transferencia de 12 ubicaciones de centros de tratamiento en Nueva Jersey a Klein, y el pago de aproximadamente 110,000 dólares estadounidenses en impuestos sobre la nómina. A cambio, Klein renunciará a 11,634,660 acciones ordinarias de Greenbrook, que serán canceladas. Esto reduce el total de acciones en circulación a 33,967,600. Se espera que el acuerdo se cierre alrededor del 15 de agosto de 2024. El CEO de Greenbrook, Bill Leonard, expresó su satisfacción por la resolución de la disputa, permitiendo a la empresa centrarse en sus operaciones comerciales y crecimiento.
Greenbrook TMS Inc. (OTC: GBNHF)는 델라웨어에 제기된 소송을 해결하기 위해 Benjamin Klein 및 기타 원고들과 합의 계약을 체결했습니다. 이 합의에는 800,000달러의 현금 지급, Klein에게 뉴저지에 위치한 12개의 치료 센터 전환이 포함되며, 약 110,000달러의 급여세 지급이 있습니다. 그 대가로, Klein은 11,634,660주의 보통주를 포기할 것이며, 이는 취소됩니다. 이로 인해 총 유통 주식 수는 33,967,600주로 감소합니다. 합의는 2024년 8월 15일경에 완료될 것으로 예상됩니다. Greenbrook의 CEO인 Bill Leonard는 분쟁 해결에 대한 만족감을 표명하며, 이를 통해 회사가 핵심 사업 운영 및 성장에 집중할 수 있다고 밝혔습니다.
Greenbrook TMS Inc. (OTC: GBNHF) a conclu un accord de règlement avec Benjamin Klein et d'autres plaignants pour résoudre un procès intenté dans le Delaware. L'accord comprend un paiement en espèces de 800 000 dollars américains, le transfert de 12 centres de traitement dans le New Jersey à Klein, et le paiement de environ 110 000 dollars américains en taxes sur les salaires. En retour, Klein renoncera à 11 634 660 actions ordinaires de Greenbrook, qui seront annulées. Cela réduit le total des actions en circulation à 33 967 600. L'accord devrait être finalisé aux alentours du 15 août 2024. Le CEO de Greenbrook, Bill Leonard, a exprimé sa satisfaction quant à la résolution du différend, permettant à l'entreprise de se concentrer sur ses opérations commerciales essentielles et sa croissance.
Greenbrook TMS Inc. (OTC: GBNHF) hat eine Vergleichsvereinbarung mit Benjamin Klein und anderen Klägern getroffen, um eine in Delaware eingereichte Klage zu lösen. Der Vergleich umfasst eine Barzahlung von 800.000 US-Dollar, die Übertragung von 12 Behandlungszentren in New Jersey an Klein, und die Zahlung von ungefähr 110.000 US-Dollar an Lohnsteuern. Im Gegenzug wird Klein 11.634.660 Stammaktien von Greenbrook aufgeben, die annulliert werden. Dadurch verringert sich die Gesamtzahl der ausgegebenen Aktien auf 33.967.600. Der Vergleich wird voraussichtlich um den 15. August 2024 geschlossen. Der CEO von Greenbrook, Bill Leonard, äußerte seine Zufriedenheit über die Beilegung des Streits, die es dem Unternehmen ermöglicht, sich auf seine Kernaktivitäten und das Wachstum zu konzentrieren.
- Resolution of legal dispute, reducing uncertainty and potential future litigation costs
- Reduction of 11,634,660 outstanding shares, potentially increasing value for remaining shareholders
- Transfer of 12 Treatment Center locations in New Jersey, potentially streamlining operations
- Cash settlement of US$800,000, impacting the company's financial resources
- Additional payment of approximately US$110,000 in payroll taxes, plus interest and penalties
- Loss of 12 Treatment Center locations in New Jersey, potentially reducing revenue streams
Pursuant to the Settlement Agreement and in full satisfaction of the claims, Greenbrook has agreed to (i) pay the Plaintiffs a cash settlement amount equal to
In conjunction with the Settlement, Mr. Klein will relinquish to the Company all of the 11,634,660 common shares of Greenbrook (the "Klein Shares") beneficially owned, controlled or directed, directly or indirectly, by Mr. Klein that were issued in connection with the Company's acquisition of Success TMS in July 2022 (which includes 2,908,665 common shares of Greenbrook that were held in escrow and will be released back to the Company). The Klein Shares will be returned to treasury for cancellation, following which there will be 33,967,600 common shares of Greenbrook ("Common Shares") issued and outstanding.
The Settlement Agreement is not an admission of liability by either party and the parties have agreed to arrange for the immediate dismissal, with prejudice, of all claims, counterclaims and appeals relating to the dispute, thereby eliminating the uncertainty, distraction and expense of continued litigation between the parties. The parties have also agreed to mutual releases in respect of the matter.
"We are encouraged to be putting this lawsuit behind us," commented Bill Leonard, President and Chief Executive Officer of Greenbrook. "Since the commencement of the dispute, both parties have worked amicably to achieve a viable resolution. With today's announcement, we have taken an important step to permanently resolve this matter, which will allow us to fully concentrate on operating and growing our business."
About Greenbrook TMS Inc.
Operating through 130 Company-operated Treatment Centers (118 Treatment Centers following completion of the Settlement), Greenbrook is a leading provider of Transcranial Magnetic Stimulation ("TMS") and Spravato® (esketamine nasal spray), FDA-cleared, non-invasive therapies for the treatment of Major Depressive Disorder ("MDD") and other mental health disorders, in
Cautionary Note Regarding Forward-Looking Information
Certain statements contained in this press release, including statements relating to the Settlement described herein, the expected closing date thereof and its impact on the Company's financial position, liquidity, capital resources and cash flows, and the expected relinquishment and return to treasury for cancellation of the Klein Shares, may constitute "forward-looking information" within the meaning of applicable securities laws in
Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including, without limitation: macroeconomic factors such as inflation and recessionary conditions, substantial doubt regarding the Company's ability to continue as a going concern due to recurring losses from operations; inability to increase cash flow and/or raise sufficient capital to support the Company's operating activities and fund its cash obligations, repay indebtedness and satisfy the Company's working capital needs and debt obligations; prolonged decline in the price of the Company's Common Shares reducing the Company's ability to raise capital; inability to satisfy debt covenants under its credit agreement (the "Credit Agreement") and the potential acceleration of indebtedness; risks related to the ability to continue to negotiate amendments to the Credit Agreement to prevent a default; risks relating to the Company's ability to deliver and execute on the previously-announced restructuring plan (the "Restructuring Plan") and the possible failure to complete the Restructuring Plan on terms acceptable to the Company or its suppliers (including Neuronetics, Inc.), or at all; risks relating to maintaining an active, liquid and orderly trading market for Common Shares as a result of the delisting of the Common Shares from Nasdaq Capital Market of the Nasdaq Stock Market LLC; risks related to the Company's negative cash flows, liquidity and its ability to secure additional financing; increases in indebtedness levels causing a reduction in financial flexibility; inability to achieve or sustain profitability in the future; inability to secure additional financing to fund losses from operations and satisfy the Company's debt obligations; risks relating to strategic alternatives, including restructuring or refinancing of the Company's debt, seeking additional debt or equity capital, reducing or delaying the Company's business activities and strategic initiatives, or selling assets, other strategic transactions and/or other measures, including obtaining bankruptcy protection, and the terms, value and timing of any transaction resulting from that process; claims made by or against the Company, which may be resolved unfavorably to us; risks relating to the Company's dependence on Neuronetics, Inc. as its exclusive supplier of TMS devices; risks and uncertainties relating to the restatement of our financial statements for the year ended December 31, 2022 and the quarter ended September 30, 2023, including any potential litigation and/or regulatory proceedings as well as any adverse effect on investor confidence and our reputation. Additional risks and uncertainties are discussed in the Company's materials filed with the Canadian securities regulatory authorities and the United States Securities and Exchange Commission SEC from time to time (including, but not limited to, the Company's Annual Report on Form 10-K for the year ended December 31, 2023), available at www.sedarplus.ca and www.sec.gov, respectively. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
View original content:https://www.prnewswire.com/news-releases/greenbrook-announces-settlement-of-lawsuit-with-benjamin-klein-302219181.html
SOURCE Greenbrook TMS Inc.
FAQ
What is the cash settlement amount Greenbrook TMS (GBNHF) agreed to pay in the lawsuit?
How many common shares of Greenbrook TMS (GBNHF) will be cancelled as a result of the settlement?
When is the expected closing date for the settlement between Greenbrook TMS (GBNHF) and Benjamin Klein?
How many Treatment Center locations is Greenbrook TMS (GBNHF) transferring to Benjamin Klein as part of the settlement?
